Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Gastrointestinal tumours, non-colorectal

6574 - Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Date

28 Sep 2019

Session

Poster Discussion – Gastrointestinal tumours, non-colorectal

Presenters

Ahmed Kaseb

Citation

Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394

Authors

A. Kaseb1, D.G. Duda2, H.S. Tran Cao3, Y.I. abugabal4, L.M. Vence5, A. rashid6, R. carmagnani pestana7, J.M. Blando8, S. Singh8, J.N. vauthey9, Y.S. chun3, C.D. tzeng3, D. Sakamuri4, R.A. wolff4, J.C. Yao1, J. Allison10, P. Sharma11

Author affiliations

  • 1 Gi Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - houston/US
  • 2 Oncology, Massachusetts Gen Hosp, Harvard Med School, 02114 - Boston/US
  • 3 Surgical Oncology, The University of texas, MD Anderson Cancer Center, 77030 - houston/US
  • 4 Gi Medical Oncology, The University of texas, MD Anderson Cancer Center, 77030 - houston/US
  • 5 Immunology, The University of texas, MD Anderson Cancer Center, 7730 - HOUSTON/US
  • 6 Pathology, The University of texas, MD Anderson Cancer Center, 77030 - houston/US
  • 7 Cancer Med, The University of texas, MD Anderson Cancer Center, 77030 - houston/US
  • 8 Immunology, MD Anderson Cancer Center, 77030 - Houston/US
  • 9 Surgical Oncology, The University of texas, MD Anderson Cancer Center, 77030 - HOUSTON/US
  • 10 Immunology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 11 Genitourinary Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 6574

Background

In HCC, surgical resection is associated with high recurrence rates, and no effective neoadjuvant or adjuvant therapies currently exist. Immunotherapy using anti-PD-1 antibodies has shown promised but limited increase in survival in advanced disease. To maximize the benefit, we are studying the efficacy and safety of anti–PD-1 (nivolumab) and anti–CTLA-4 (ipilimumab) antibodies against HCC for resectable HCC.

Methods

This is a randomized phase II trial of nivolumab (Arm A) or nivolumab + ipilimumab (Arm B) as pre-operative treatment for patients (pts) with HCC who are eligible for surgical resection. Pts are given nivolumab 240 mg every 2 weeks (wks) for a total of 6 wks. Pt in Arm B are treated concurrently with ipilimumab 1 mg/kg every 6 wks. Surgical resection occurs within 4 wks after last cycle of therapy. Pts continue adjuvant immunotherapy for up to 2 years after resection. The primary objective is the safety/tolerability of nivolumab +/- ipilimumab. Secondary objectives include overall response rate, complete response rate and time to progression. Exploratory objectives include evaluating the pre- and post-treatment immunological changes in tumor tissues and peripheral blood.

Results

Twenty-six patients were enrolled at the time of this interim analysis, of which 20 have evaluable data.Most pts (55%) were between 60-70yo and male (75%).Seven pts were HCV-positive, 7 had HBV and 6 had no hepatitis. 20 patients proceeded with resection as planned but surgery was aborted for 3 patients (1 for frozen abdomen and 2 development of contralateral liver nodule). Three are still receiving preoperative therapy. Pathologic complete response (pCR) was observed in 5/20 evaluable patients – 2 in Arm A and 3 Arm B (25% pCR rate). Five patients in Arm B and 1 in Arm A experienced grade 3 or higher toxicity prior to surgery. No grade 4 or higher toxicity were observed.

Conclusions

We report a pCR rate of 25% for resectable HCC after preoperative immunotherapy in a randomized phase II pilot trial. Treatment was safe and surgical resection was not delayed. The study is ongoing. These promising results may contribute to a paradigm shift in the perioperative treatment of resectable HCC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

BMS Pharmaceuticals.

Funding

BMS Pharmaceuticals.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.